These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
264 related articles for article (PubMed ID: 21119337)
1. Prasugrel: an efficacy and safety review of a new antiplatelet therapy option. Armani AM Crit Pathw Cardiol; 2010 Dec; 9(4):199-202. PubMed ID: 21119337 [TBL] [Abstract][Full Text] [Related]
2. Emerging antiplatelet therapies in percutaneous coronary intervention: a focus on prasugrel. Martin MT; Spinler SA; Nutescu EA Clin Ther; 2011 Apr; 33(4):425-42. PubMed ID: 21635989 [TBL] [Abstract][Full Text] [Related]
8. Prasugrel: a critical comparison with clopidogrel. Reinhart KM; White CM; Baker WL Pharmacotherapy; 2009 Dec; 29(12):1441-51. PubMed ID: 19947804 [TBL] [Abstract][Full Text] [Related]
9. Prasugrel: Clinical development and therapeutic application. Guerra DR; Tcheng JE Adv Ther; 2009 Nov; 26(11):999-1011. PubMed ID: 20020231 [TBL] [Abstract][Full Text] [Related]
10. Implementation of contemporary oral antiplatelet treatment guidelines in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the GReek AntiPlatelet rEgistry (GRAPE). Alexopoulos D; Goudevenos JA; Xanthopoulou I; Deftereos S; Sitafidis G; Kanakakis I; Hamilos M; Parissis H; Ntalas IV; Angelidis C; Petousis S; Vavuranakis M; Hahalis G; Stefanadis C; Int J Cardiol; 2013 Oct; 168(6):5329-35. PubMed ID: 23978364 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials. Mariani M; Mariani G; De Servi S Expert Rev Cardiovasc Ther; 2009 Jan; 7(1):17-23. PubMed ID: 19105763 [TBL] [Abstract][Full Text] [Related]
12. Treatment patterns and outcomes in patients undergoing percutaneous coronary intervention treated with prasugrel or clopidogrel (from the Swedish Coronary Angiography and Angioplasty Registry [SCAAR]). Damman P; Varenhorst C; Koul S; Eriksson P; Erlinge D; Lagerqvist B; James SK Am J Cardiol; 2014 Jan; 113(1):64-9. PubMed ID: 24169009 [TBL] [Abstract][Full Text] [Related]
13. Antiplatelet therapy in patients with ST-elevation myocardial infarction undergoing myocardial revascularisation: beyond clopidogrel. Wouter Jukema J; Collet JP; De Luca L Curr Med Res Opin; 2012 Feb; 28(2):203-11. PubMed ID: 22181345 [TBL] [Abstract][Full Text] [Related]
14. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Wiviott SD; Antman EM; Winters KJ; Weerakkody G; Murphy SA; Behounek BD; Carney RJ; Lazzam C; McKay RG; McCabe CH; Braunwald E; Circulation; 2005 Jun; 111(25):3366-73. PubMed ID: 15967851 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Wiviott SD; Antman EM; Gibson CM; Montalescot G; Riesmeyer J; Weerakkody G; Winters KJ; Warmke JW; McCabe CH; Braunwald E; Am Heart J; 2006 Oct; 152(4):627-35. PubMed ID: 16996826 [TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245 [TBL] [Abstract][Full Text] [Related]
17. Prasugrel: a guide to its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention in the US. Lyseng-Williamson KA Am J Cardiovasc Drugs; 2012 Jun; 12(3):207-16. PubMed ID: 22583148 [TBL] [Abstract][Full Text] [Related]
18. Role of prasugrel, a novel P2Y(12) receptor antagonist, in the management of acute coronary syndromes. Baker WL; White CM Am J Cardiovasc Drugs; 2009; 9(4):213-29. PubMed ID: 19655817 [TBL] [Abstract][Full Text] [Related]
19. Safety of reloading prasugrel in addition to clopidogrel loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Loh JP; Pendyala LK; Kitabata H; Torguson R; Chen F; Kent KM; Satler LF; Suddath WO; Pichard AD; Waksman R Am J Cardiol; 2013 Mar; 111(6):841-5. PubMed ID: 23273719 [TBL] [Abstract][Full Text] [Related]
20. Acute coronary syndromes: identifying the appropriate patient for prasugrel. Stephens JC; Askari AT Postgrad Med; 2012 Mar; 124(2):16-28. PubMed ID: 22437212 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]